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ABSTRACT
Objective To investigate any long term effects onmortality
in participants in experimental research related to
chemical warfare agents from 1941 to 1989.
Design Historical cohort study.
Data sourcesArchive of UK government research facility at
Porton Down, UK military personnel records, and national
death and cancer records.
Participants18276malemembers of theUKarmed forces
who had spent one or more short periods (median 4 days
between first and last test) at Porton Down and a
comparison group of 17600 non-Porton Down veterans
followed to 31 December 2004.
Main outcome measuresMortality rate ratio of Porton
Down compared with non-Porton Down veterans and
standardised mortality ratio of each veteran group
compared with the general population. Both ratios
adjusted for age group and calendar period.
Results Porton Down veterans were similar to non-Porton
Down veterans in year of enlistment (median 1951) but
had longermilitary service (median6.2 v5.0 years). After a
median follow-upof 43 years, 40% (7306) of Porton Down
and 39% (6900) of non-Porton Down veterans had died.
All cause mortality was slightly greater in Porton Down
veterans (rate ratio 1.06, 95% confidence interval 1.03 to
1.10, P<0.001), more so for deaths outside the UK (1.26,
1.09 to 1.46). Of 12 cause specific groups examined, rate
ratios in Porton Down veterans were increased for deaths
attributed to infectious and parasitic (1.57, 1.07 to 2.29),
genitourinary (1.46, 1.04 to 2.04), circulatory (1.07, 1.01
to 1.12), and external (non-medical) (1.17, 1.00 to 1.37)
causes and decreased for deaths attributed to in situ,
benign, and unspecified neoplasms (0.60, 0.37 to 0.99).
There was no clear relation between type of chemical
exposure and cause specific mortality. The mortality in
both groups of veteranswas lower than that in the general
population (standardised mortality ratio 0.88, 0.85 to
0.90; 0.82, 0.80 to 0.84).
ConclusionsMortality was slightly higher in Porton Down
than non-Porton Down veterans. With lack of information
on other important factors, such as smoking or service
overseas, it is not possible to attribute the small excess
mortality to chemical exposures at Porton Down.
INTRODUCTION
After the use of chemical warfare agents in the first
world war, the UK government initiated research at
Porton Down to study their potential impact on
military capability and the effectiveness of protective
measures.1-5 This included a “human volunteer pro-
gramme” in which, since 1916, at least 30 000 people,
mainly servicemen are thought to have taken part.3
After ex-servicemen expressed concern about whether
participation might have damaged their health in the
long term, the UK government commissioned this
epidemiological study in 2002. There have been few
studies of participants in such human experimental
programmes6-9 and results from mortality studies in
American servicemen have been inconclusive.7-10 A
recent survey of members of a UK veterans’ support
group found them to report poorer quality of life than
the general population.11 This is the first report of
mortality and cancer morbidity12 in the cohort of
British participants in the chemical tests at Porton
Down.
METHODS
Assembly of the Porton Down veteran cohort
Ourpilot study found that service number, essential for
retrieving military personnel files, was routinely
recorded at Porton Down only from 1 April 1941.
Our cohort comprised all members of the UK armed
forces recorded as having participated in the “human
volunteer programme” from 1 April 1941 to 31
December 1989. We initially identified potential
cohort members using a database of 20 006 names
previously abstracted by a team employed by the
Ministry of Defence from documents in the historical
archive at Porton Down. This was compared against
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the names identified during our abstraction of expo-
sure data.
Names and service numbers were submitted to the
relevant military personnel records authority: army,
air force, navy, andmarines.We excluded civilian staff
(n=344) and members of non-UK armed forces
(n=220). Personnel files were successfully retrieved for
18 441 Porton Down veterans, and identifiers neces-
sary for data linkage were manually abstracted and
enteredwith a standard format onto a secure computer.
For army veterans, this was carried out by a team of six
people employed by the University of Oxford and
based at the army personnel archive. For army
personnel still in active service, and for air force,
navy, and marine veterans, Ministry of Defence
employees trained by the research team abstracted
data. The research team directed quality control
procedures at all sites.
Where possible, data on service number, name, sex,
date and place of birth, mother’s maiden name, NHS
number, national registration identity number,
national insurance number, dates of recruitment and
discharge (with corresponding addresses, service
numbers, and ranks), and date of death were
abstracted. Names of veterans whose personnel files
could not be located after identification details were
checked and after a secondattempt at file retrievalwere
submitted to the Ministry of Defence for circulation to
relevant central departments. All data abstracted from
personnel files were returned to the university and
checked for data abstraction or entry errors. Any data
discrepancies later identified were corrected, when
appropriate.
Assembly of the comparison cohort
We identified a comparison group of veterans who did
not visit Porton Down (“non-Porton Down veterans”).
Our pilot study showed that a sample of veterans with
adjacent servicenumbers toPortonDownveteranshad
similar distributions of important characteristics, such
as date of birth. So, within each branch of the military,
we generated a service number adjacent to (above or
below) that of each PortonDownveteran and retrieved
the corresponding personnel file for data abstraction
and entry in the same way as for the Porton Down
veterans. If a filewas not found, the alternative adjacent
service number was submitted and, if necessary, the
process repeated. Personnel files were successfully
retrieved for 18 103 non-Porton Down veterans and
over95%had servicenumbers immediatelyadjacent to
the corresponding Porton Down veteran.
Follow-up
The primary source of mortality data in the UK is the
NationalHealth Service central register (NHSCR).We
submitted the required identification details to the
register in Southport, which traced deaths, and, when
available, emigrations, for England and Wales, and
managed personnel data submission for tracing to the
registers in Scotland and Northern Ireland. Untraced
veterans were checked against the website of the
Table 1 | Characteristics of 18276 Porton Down veterans and 17600 non-Porton Down veterans.
Figures are numbers (percentages) of veterans
Characteristic Porton Down veterans Non-Porton Down veterans
Service at enlistment:
Army 11 407 (62.4) 10 872 (61.8)
Air force 4026 (22.0) 3987 (22.7)
Navy (and marines) 2843 (15.6) 2741 (15.6)
Decade of birth:
Before 1920 3742 (20.5) 3794 (21.6)
1920s 3515 (19.2) 3211 (18.2)
1930s 6088 (33.3) 5977 (34.0)
1940s or later 4931 (27.0) 4618 (26.2)
Place of birth:
England 14 295 (79.2) 13 761 (78.9)
Wales 931 (5.2) 919 (5.3)
Scotland 1785 (9.9) 1803 (10.3)
Northern Ireland 307 (1.7) 248 (1.4)
Republic of Ireland 265 (1.5) 261 (1.5)
Overseas 458 (2.5) 444 (2.5)
Missing 235 164
Age (years) at enlistment:
<16 1237 (6.8) 1220 (6.9)
16-<18 4987 (27.4) 4290 (24.4)
18-<20 6495 (35.7) 6211 (35.3)
20-<22 2270 (12.5) 2354 (13.4)
≥22 3226 (17.7) 3517 (20.0)
Missing 61 8
Period at enlistment*:
Before second world war 975 (5.4) 884 (5.0)
During second world war 5275 (29.0) 5048 (28.7)
After second world war 7814 (42.9) 7667 (43.6)
After national service 4151 (22.8) 3993 (22.7)
Missing 61 8
Rank at enlistment:
Private (or equivalent) 18 094 (99.3) 17 438 (99.4)
Other 122 (0.7) 112 (0.6)
Missing 60 50
Duration of service at first visit to Porton Down (years):
<2 8160 (44.8) NA
2-<3 3087 (17.0) NA
3-<5 3572 (19.6) NA
5-<10 2341 (12.9) NA
≥10 1055 (5.8) NA
Missing 61
Total duration of service (years)†:
<2 438 (2.4) 2771 (15.8)
2-<3 2830 (15.6) 3406 (19.4)
3-<5 2823 (15.6) 2728 (15.5)
5-<10 7011 (38.6) 5565 (31.6)
≥10 5043 (27.8) 3117 (17.7)
Missing 131 13
Vital status at 31 December 2004:
Alive 10 409 (57.0) 10 222 (58.1)
Deceased 7306 (40.0) 6900 (39.2)
Follow-up censored at:
Discharge from services 438 (2.4) 346 (2.0)
Emigration 68 (0.4) 69 (0.4)
Other 55 (0.3) 63 (0.4)
NA=not applicable.
*Second world war dates taken as 1 September 1939 to 30 April 1945; national service dates taken as 1 May 1945 to 31
December 1960.
†Includes 148 Porton Down veterans, and 132 non-Porton Down veterans still serving at time of data abstraction.
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CommonwealthWarGravesCommission (CWGC), a
registry of deaths inCommonwealth service personnel
occurring in the two world wars between 1914 and
1947 (www.cwgc.org). Names not traced by NHSCR
and not found on the commission’s website were
submitted to the Department for Work and Pensions
(DWP) for classification as dead, alive, or vital status
not known. For veterans identified by the DWP as
having died, we obtained copies of death certificates,
when available, from NHSCR.
Each conditionon the death certificate, including the
underlying cause, was coded by theOffice forNational
Statistics according to ICD-10 (international classifica-
tion of diseases, 10th revision). Death certificates were
not available for deaths not registered in the UK, so
cause of death was unknown.
Exposures of Porton Down veterans
To assess exposure we used contemporaneous experi-
mental records in the Porton Down historical archive
following a protocol reported elsewhere.13 14 In brief,
data abstraction involved linking, when possible, each
test to an individual veteran and the classification of
that test as involving a chemical or not. Each chemical
test was classified as involving vesicant(s), nerve agent
(s), or other chemical(s). For vesicants (blistering
agents) and nerve agents, detailed information relating
to exposure was abstracted.14 For analyses reported
here, we grouped Porton Down veterans as ever or
never exposed at least once to any chemical, any
vesicant, anynerve agent, or anyother chemical, and to
specific chemicals to which at least 1000 veterans had
been exposed. “High” exposure subgroups were
defined as elsewhere.14
Mortality analysis
We decided on the classifications of exposures and
causes of death before we linked the exposure and
outcome databases. Analyses reported relate to under-
lying cause of death in 18 276 male Porton Down
veterans and 17 600 male non-Porton Down veterans,
excluding women (134 and 127 respectively) and men
with missing data (31 and 376 respectively). All
analyses used STATA version 8.2 (www.stata.com).
SignificancewasdefinedasP<0.05with two sided tests.
Comparisonwith nationalmortality rates—Personyears
of follow-up for PortonDownveterans started from the
earliest date (after 1 April 1941) they were recorded as
included in a test at PortonDown; for the 973 forwhom
a test date was not available, we counted person years
from the date of arrival at Porton Down as recorded in
theMinistryofDefencedatabase.Personyears fornon-
Porton Down veterans started from a date derived by
adding to the enlistment date the interval between the
dates of the corresponding Porton Down veteran’s
enlistment and first visit to Porton Down. For the 65
non-PortonDown veterans for whomwe did not know
date of enlistment, we counted person years from the
same date as for the corresponding Porton Down
veteran. Person years stopped at the earliest of date of
death, loss to follow-up, or 31 December 2004. For
losses to follow-up,we censored person years at the last
known date alive in the UK (such as date of emigration
or date of discharge from the services). We stratified
person years and deaths according to 15 five year age
Vesicants
(n=10 539)
Nerve agents
(n=3597)
Other chemicals
(n=11 925)
55353911
1206
1273
963
3643
155
Fig 1 | Overlap of exposure groups in 16686 Porton Down
veterans (excludes 1590 not recorded as exposed to any
chemical)
Table 2 | Summary of exposures in 18 276 Porton Down
veterans, 1941-89
No (%) of veterans
No of tests:
1 2173 (11.9)
2-5 4161 (22.8)
6-9 3814 (20.9)
10-14 3080 (16.9)
≥15 4075 (22.3)
None 973 (5.3)
Decade of first test*:
1940s 6504 (35.6)
1950s 6097 (33.4)
1960s 2260 (12.4)
1970s 1966 (10.8)
1980s 1449 (7.9)
No of chemical tests†:
≥1 16 686 (91.3)
None 1590 (8.7)
Type of chemical test†:
Vesicant:
Any 10 539 (57.7)
Sulphur mustard‡ 10 273 (56.2)
Lewisite 1745 (9.5)
Nitrogen mustard 1183 (6.5)
Nerve agent:
Any 3597 (19.7)
Sarin 2980 (16.3)
Other chemical:
Any 11 925 (65.2)
CS 1328 (7.3)
CR 1175 (6.4)
Pralidoxime 1696 (9.3)
Atropine 1577 (8.6)
*Date of first visit for those with no test data.
†Includes 17 303 veterans for whom type of test could be determined.
‡Includes mustard sensitivity tests.
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groups (15-19, 20-24, etc, to≥85) andbysingle calendar
year (from 1941 to 2004). We calculated expected
deaths by multiplying the person years for each five
year age group and single calendar year by the
corresponding national rates for England, Wales, and
Scotland and estimated standardised mortality ratios
Table 3 | All causemortality in Porton Down veterans and non-Porton Down veterans comparedwith nationalmortality rates according
to service at enlistment. Standardised mortality ratios (95% confidence intervals) adjusted for calendar year and age group
Porton Down veterans Non-Porton Down veterans
Observed deaths* Standardised mortality ratio Observed deaths* Standardised mortality ratio
All veterans 6885 0.88 (0.85 to 0.90) 6582 0.82 (0.80 to 0.84)
Service at enlistment:
Army 5100 0.88 (0.86 to 0.91) 4892 0.84 (0.81 to 0.86)
Air force 965 0.77 (0.72 to 0.82) 929 0.72 (0.68 to 0.77)
Navy (and marines) 820 0.97 (0.90 to 1.03) 761 0.88 (0.81 to 0.94)
*Includes deaths registered in UK.
All deaths
  UK  deaths
  Overseas deaths
UK deaths by cause group 
  Infectious and parasitic
  Malignant neoplasms
  In situ, benign, and unspecified neoplasms
  Endocrine, nutritional, and metabolic
  Mental and behavioural
  Nervous system
  Circulatory system
  Respiratory system
  Digestive system
  Musculoskeletal system
  Genitourinary system
  External causes
1.06 (1.02 to 1.10)
1.05 (1.01 to 1.09)
1.25 (1.07 to 1.46)
 
1.41 (0.94 to 2.12)
1.02 (0.95 to 1.09)
0.47 (0.26 to 0.87)
1.01 (0.69 to 1.48)
1.05 (0.71 to 1.58)
0.93 (0.71 to 1.22)
1.06 (1.00 to 1.12)
1.05 (0.94 to 1.18)
1.06 (0.86 to 1.32)
0.89 (0.49 to 1.62)
1.44 (1.01 to 2.06)
1.23 (1.02 to 1.48)
5444
5099
345
 
49
1503
15
48
42
85
2280
558
148
19
65
211
No of
deaths
Rate ratio
(95% CI)
Any vesicant
5299
4960
339
 
48
1464
14
46
41
82
2216
543
144
19
63
207
No of
deaths
Rate ratio
(95% CI)
Any sulphur mustard
1.06 (1.02 to 1.10)
1.05 (1.01 to 1.09)
1.27 (1.08 to 1.48)
   
 1.42 (0.94 to 2.14)
1.02 (0.95 to 1.09)
0.46 (0.25 to 0.85)
1.00 (0.68 to 1.46)
1.06 (0.70 to 1.58)
0.92 (0.70 to 1.21)
1.06 (1.00 to 1.12)
1.05 (0.93 to 1.18)
1.06 (0.86 to 1.32)
0.91 (0.50 to 1.66)
1.43 (1.00 to 2.05)
1.24 (1.03 to 1.49)
All deaths
  UK  deaths
  Overseas deaths
UK deaths by cause group 
  Infectious and parasitic
  Malignant neoplasms
  In situ, benign, and unspecified neoplasms
  Endocrine, nutritional, and metabolic
  Mental and behavioural
  Nervous system
  Circulatory system
  Respiratory system
  Digestive system
  Musculoskeletal system
  Genitourinary system
  External causes
1.16 (1.09 to 1.23)
1.15 (1.08 to 1.22)
1.28 (1.01 to 1.61)
    
 1.85 (0.95 to 3.46)
1.07 (0.95 to 1.20)
0.97 (0.36 to 2.26)
1.41 (0.71 to 2.64)
1.07 (0.50 to 2.13)
1.27 (0.81 to 1.99)
1.16 (1.06 to 1.27)
1.18 (0.99 to 1.41)
1.17 (0.80 to 1.73)
1.46 (0.52 to 3.58)
1.53 (0.82 to 2.73)
1.18 (0.80 to 1.74)
1395
1291
104
 
16
356
7
14
11
25
598
158
33
7
17
32
0.25 0.5 1.0 2.0 4.0
Rate ratio
Any Lewisite
913
850
63
 
2
249
1
5
11
14
391
103
22
5
14
22
0.25 0.5 1.0 2.0 4.0
Rate ratio
Any nitrogen mustard
1.06 (0.99 to 1.14)
1.06 (0.98 to 1.14)
1.12 (0.85 to 1.48)
     
0.31 (0.04 to 1.22)
1.05 (0.92 to 1.21)
0.19 (0.00 to 1.17)
0.73 (0.22 to 1.86)
1.40 (0.65 to 2.76)
1.03 (0.54 to 1.84)
1.06 (0.95 to 1.18)
1.06 (0.86 to 1.31)
1.10 (0.70 to 1.74)
1.43 (0.42 to 3.94)
1.73 (0.88 to 3.21)
1.17 (0.74 to 1.86)
Fig 2 | Rate ratios for cause specific mortality in Porton Down veterans included in test(s) involving vesicant(s) compared with non-Porton
Down veterans, adjusted for age and calendar period. Rate ratio estimates are represented by box with size inversely proportional to
variance. Vertical dotted line shows estimate for all deaths. For clarity, only rows for major ICD chapter headings are presented
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from the ratio of observed to expected deaths. We
obtained 95% confidence intervals and tests of
significance using the normal approximation to the
Poisson distribution.
Comparison of mortality between Porton Down and non-
Porton Down veterans—Person years were calculated as
above except that we did not censor losses to follow-up
at the last known date alive in the UK. We estimated
adjusted rate ratios and 95% confidence intervals and
derived P values by theMantel-Haenszel method with
deaths andpersonyears stratifiedaccording to fiveyear
age groups (as above) and five year calendar periods
(1941-4, 1945-9, etc, to 2000-4).15When the number of
expected deaths in either group of veterans was less
than 10,we estimated adjusted rate ratios and tested for
significance by fitting exact conditional Poisson
regression models to the stratified data.16 Following
the approach to exposure outlined above, we com-
pared mortality rates in specific exposure groups of
Porton Down veterans with that of all non-Porton
Down veterans. For groups of causes where there was
either a prior hypothesis of association, or the data
suggested an association, we calculated rate ratios for
subgroups with “high” exposure.14
Table 4 | Cause specific mortality in Porton Down veterans compared with non-Porton Down veterans. Rate ratios (95%
confidence intervals) with and without adjustment for age group and calendar period
Observed deaths Rate ratio
Porton Down
veterans
Non-Porton Down
veterans Unadjusted
Adjusted
(95% CI)
All causes (ICD-10 code)
Total 7306 6900 1.03 1.06*** (1.03 to 1.10)
All deaths registered in UK (A00-Z99) 6885 6582 1.02 1.06** (1.02 to 1.09)
All deaths not registered in UK 421 318 1.29*** 1.26** (1.09 to 1.46)
Cause specific mortality in UK (ICD-10 code)
Infectious and parasitic (A00-B99) 66 43 1.49 1.57* (1.07 to 2.29)
Malignant neoplasms:
All (C00-97) 2093 2041 1.00 1.03 (0.97 to 1.10)
Upper aerodigestive (C00-14, C30-32) 59 57 1.01 1.03 (0.71 to 1.48)
Oesophagus (C15) 86 99 0.85 0.87 (0.65 to 1.16)
Stomach (C16) 152 137 1.08 1.13 (0.89 to 1.42)
Intestine and rectum (C17-20) 198 188 1.02 1.06 (0.87 to 1.30)
Pancreas (C25) 83 89 0.91 0.94 (0.70 to 1.27)
Trachea, bronchus, and lung (C33,C34) 785 726 1.05 1.09 (0.98 to 1.21)
Melanoma and other skin (C43,C44) 26 31 0.82 0.83 (0.49 to 1.40)
Prostate (C61) 146 149 0.95 1.01 (0.80 to 1.27)
Urinary tract (C64-68) 122 126 0.94 0.98 (0.76 to 1.26)
Brain and other central nervous system (C71, C72) 46 58 0.77 0.78 (0.53 to 1.15)
All lymphatic and haematopoietic (C81-96) 128 132 0.94 0.96 (0.76 to 1.23)
All other malignant neoplasms† 262 249 1.02 1.06 (0.89 to 1.26)
In situ, benign, and unspecified neoplasms (D10-48) 25 42 0.58* 0.60* (0.37 to 0.99)
Endocrine, nutritional, and metabolic (E00-90) 65 70 0.90 0.94 (0.67 to 1.31)
Mental and behavioural (F00-99) 53 51 1.01 1.08 (0.73 to 1.59)
Nervous system (G00-99) 104 132 0.77 0.80 (0.62 to 1.03)
Circulatory system:
All (I00-99) 3007 2851 1.03 1.07* (1.01 to 1.12)
Ischaemic heart diseases (I20-25) 2021 1884 1.04 1.08* (1.01 to 1.15)
Cerebrovascular diseases (I60-69) 504 501 0.98 1.03 (0.91 to 1.17)
All other circulatory (I00-19, I26-59, I70-99) 482 466 1.01 1.05 (0.93 to 1.20)
Respiratory system:
All (J00-99) 694 662 1.02 1.07 (0.96 to 1.19)
Chronic lower respiratory tract (J40-47) 426 417 0.99 1.04 (0.91 to 1.19)
All other respiratory (J00-39, J48-99) 268 245 1.06 1.12 (0.94 to 1.33)
Digestive system (K00-93) 218 206 1.03 1.05 (0.87 to 1.27)
Musculoskeletal system and connective tissue (M00-99) 23 27 0.83 0.87 (0.50 to 1.51)
Genitourinary system (N00-99) 81 57 1.38 1.46* (1.04 to 2.04)
All external causes (S00-T98, V01-Y98) 341 284 1.17 1.17* (1.00 to 1.37)
All other UK deaths with ICD code‡ 44 39 1.10 1.12 (0.73 to 1.73)
All other UK deaths with no ICD code 71 77 0.90 0.92 (0.67 to 1.27)
†C21-24, C26-29, C37-41, C45-50, C60, C62, C63, C69, C70, C73-80, C97.
‡D50-89, H00-95, L00-99, Q00-99, R00-99, U00-89, Z00-99.
*P<0.05; **P<0.01; ***P<0.001.
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RESULTS
Of the Porton Down veterans, 62% (11 407/18 276)
had joined the army, 22% (4026) the air force, and 16%
(2843) the navy, including the marines. As expected,
the distribution of service at enlistment of the 17 600
non-Porton Down veterans was virtually identical
(table 1). Most veterans were born in England before
1940 and joined theBritish armed services as teenagers
during periods of conscription, either in the second
world war (1939-45) or in the period of compulsory
male military service (“national service”) after the war
to 1960 (table 1). The median year of enlistment was
1951 for both groups. Almost all had enlisted with the
rank of private (or equivalent). Over half of Porton
Down veterans had been in military service for less
than three years when they first went to Porton Down.
Of the military and demographic factors examined in
this study, the only clear difference between the two
cohorts was that Porton Down veterans had a longer
duration of military service. Fewer Porton Down than
non-Porton Down veterans stayed for less than two
years (2% (438/18 145) v 16% (2771/17 587)) andmore
stayed for 10 or more years (28% (5043) v 18% (3117))
(table1).Themediandurationofmilitary servicewas6.
2 years (interquartile range 4.2-11.4) for Porton Down
veterans and 5.0 (2.1-7.5) for non-Porton Down
veterans.
The median interval between first and last test
carried out at PortonDownwas four days (interquartile
range 1-8 days), and median number of days on which
tests were performedwas two (1-4).14 For 69% (12 601/
18 276) of the PortonDown veterans, the first recorded
visit toPortonDownwas in the1940sor1950s (table2).
The type of test could be determined for 95% (17 303)
of veterans and, of these, 91% (16 686) were in at least
one test involving a chemical. Fifty eight per cent of
veterans (10 539) were in at least one test involving a
vesicant, 20% (3597) a nerve agent, and 65% (11 925)
Table 5 | All cause mortality in Porton Down veterans compared with non-Porton Down veterans according to time since first
test. Rate ratios adjusted for five year age group and five year calendar period
Years since first
test
All deaths Deaths registered in UK Deaths not registered in UK
Deaths Rate ratio (95% CI) Deaths Rate ratio (95% CI) Deaths Rate ratio (95% CI)
<2 170 1.14 (0.91 to 1.42) 34 1.11 (0.68 to 1.83) 136 1.14 (0.89 to 1.47)
2-<5 144 1.29* (1.01 to 1.66) 39 0.91 (0.59 to 1.40) 105 1.53** (1.13 to 2.09)
5-<10 74 1.04 (0.76 to 1.43) 68 1.01 (0.73 to 1.41) 6 1.54 (0.44 to 5.40)
10-<20 282 1.04 (0.88 to 1.22) 270 1.03 (0.87 to 1.23) 12 1.08 (0.48 to 2.42)
20-<40 2579 1.07** (1.02 to 1.13) 2535 1.07** (1.01 to 1.13) 44 1.20 (0.77 to 1.87)
≥40 4057 1.05** (1.01 to 1.10) 3939 1.05** (1.00 to 1.10) 118 1.28 (0.97 to 1.68)
Total 7306 1.06*** (1.03 to 1.10) 6885 1.06** (1.02 to 1.09) 421 1.26** (1.09 to 1.46)
*P<0.05, **P<0.01, ***P<0.001.
All deaths
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Fig 3 | Rate ratios for cause specific mortality in Porton Down veterans included in test(s) involving nerve agent(s) compared with
non-Porton Down veterans, adjusted for age and calendar period. Rate ratio estimates are represented by box with size inversely
proportional to variance. Vertical dotted line shows estimate for all deaths. For clarity, only rows for major ICD chapter headings
are presented
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another chemical group (neither vesicant nor nerve
agent) (table 2),with considerable overlap (fig 1). There
were eight specific chemicals for which there were
records of at least 1000 Porton Down veterans having
been tested: threevesicants (sulphurmustard,Lewisite,
and nitrogen mustard), one nerve agent (sarin), two
lachrymators (CS and CR), and two anti-nerve agent
pharmaceutical chemicals (pralidoxime and atropine)
(table 2). The median number of tests per veteran was
five for vesicants, one for nerve agents, and three for
other chemicals. 14
After a median follow-up of over 40 years (median
43.2 (interquartile range 31.4-51.0) for Porton Down
and 43.7 (31.9-51.1) for non-Porton Down veterans),
40% (n=7306) of PortonDown and 39% (6900) of non-
Porton Down veterans were notified as dead (table 1).
All cause mortality in both groups was less than in the
general population, with variation by branch of the
services (table 3).
All causemortality in the PortonDown veterans was
higher than that of the comparison group (rate ratio
1.06, 95% confidence interval 1.03 to 1.10, table 4),
particularly in deaths not registered in the UK (1.26,
1.09 to 1.46). ForUKdeaths,we comparedmortality in
12groupsofunderlying causes (table4). In fourgroups,
there was a significant excess: infectious and parasitic
(1.57, 1.07 to 2.29), genitourinary (1.46, 1.04 to 2.04),
circulatory (1.07, 1.01 to 1.12), and external (non-
medical) (1.17, 1.00 to 1.37) causes. There was a
significant deficit for in situ, benign, and unspecified
neoplasms (0.60, 0.37 to 0.99).
When we restricted analysis to veterans with two or
more years of service, the all cause mortality rate ratio
was similar (1.07, 1.03 to 1.10). Rate ratios for all cause
mortality were also examined by time since first test
(table 5). The overall excess mortality relative to non-
Porton Down veterans seemed to be present at all
stages of follow-up examined.
Figures 2, 3, and 4 present rate ratios according to
chemical exposure group. The excess all cause
mortality seen in the whole cohort was seen in most
groups, as were several of the associations with cause
specific mortality. Lewisite exposure was associated
with cancers of the trachea, bronchus, and lung (1.19,
1.00 to 1.43). Table 6 presents rate ratios for selected
causes of death in subgroups with “high” exposure; in
none was the estimate higher than the upper bound of
the 95% confidence interval for the rate ratio for the
exposure group as a whole.
DISCUSSION
Mortality in men in the armed forces who took part in
tests at Porton Down from 1941-89 was slightly higher
than that of similar veterans who did not take part (rate
ratio 1.06). This excess was particularly evident in
deaths from infectious and parasitic, circulatory,
genitourinary, and external (non-medical) causes, as
well as in deaths overseas for which no underlying
cause was available. The excess in overseas deaths
might be related to the longer duration of military
service in thePortonDownveterans as theymight have
had more overseas military postings. Mortality from
cancer was not increased, a similar finding to that for
cancermorbidity.12 At the same time, overallmortality
in Porton Down veterans was 12% lower than that of
the general population. This is perhaps not surprising
because these men had all met the selection criteria for
military service; similarly lowmortalityhasbeen found
in other UK military cohorts, such as nuclear test
veterans and submariners.17 18
Strengths and weaknesses
Our cohort is the largest reported to date with
experimental exposure to chemical warfare agents
and related chemicals and includes over 17 000
exposed veterans compared with 6720 and 1545
veterans studied in the United States.7-10 As well as
collecting detailed exposure information13 14 we
assembled a comparison group of similar veterans
whodidnot attendPortonDown.Themedianduration
Table 6 | Mortality by selected underlying causes (ICD-10 code) for Porton Down veterans with
high recorded levels of exposure to specific chemicals, relative to non-Porton Down veterans.
Rate ratios adjusted for age group and calendar period (95% CI)
Chemical and indicator of high exposure No of deaths Adjusted rate ratio (95% CI)
Sulphur mustard
Dermal ≥10.63 mg:
Upper aerodigestive cancers (C00-C14, C30-C32) 10 0.76 (0.34 to 1.51)
Cancers of trachea, bronchus, and lung (C33, C34) 195 0.99 (0.84 to 1.16)
Diseases of circulatory system (I00-I99) 804 1.04 (0.96 to 1.12)
Chronic lower respiratory tract diseases (J40-J47) 118 0.99 (0.81 to 2.07)
All external causes (S00-T98, V01-Y98) 69 1.22 (0.93 to 1.60)
Dermal vesicle:
Upper aerodigestive cancers (C00-C14, C30-C32) 17 1.19 (0.68 to 2.07)
Cancers of trachea, bronchus, and lung (C33, C34) 259 1.12 (0.92 to 1.29)
Diseases of circulatory system (I00-I99) 1004 1.11** (1.01 to 1.12)
Chronic lower respiratory tract diseases (J40-J47) 162 1.13 (0.94 to 1.36)
All external causes (S00-T98, V01-Y98) 80 1.35* (1.01 to 1.75)
Lewisite
Dermal ≥13.69 mg:
Cancers of trachea, bronchus, and lung (C33, C34) 27 1.10 (0.75 to 1.61)
Melanoma and other skin cancers (C43, C44) 1 1.86 (0.04 to 12.83)
Diseases of circulatory system (I00-I99) 109 1.14 (0.94 to 1.38)
Dermal vesicle:
Cancers of trachea, bronchus, and lung (C33, C34) 73 1.25 (0.98 to 1.60)
Melanoma and other skin cancers (C43, C44) 0 0.00 (0.00 to 3.13)
Diseases of circulatory system (I00-I99) 261 1.14* (1.01 to 1.30)
Nitrogen mustard
Dermal ≥23.73 mg:
Melanoma and other skin cancers (C43, C44) 2 3.50 (0.37 to 16.21)
All lymphatic and haematopoetic (C81-C96) 3 0.83 (0.17 to 2.53)
Dermal vesicle:
Melanoma and other skin cancers (C43, C44) 1 1.65 (0.04 to 11.42)
All lymphatic and haematopoetic (C81-C96) 1 0.26 (0.01 to 1.52)
Sarin
Air ≥14.99 mg.min/m3:
Diseases of circulatory system (I00-I99) 61 1.22 (0.94 to 1.58)
Cholinesterase fall ≥30%:
Diseases of circulatory system (I00-I99) 99 1.18 (0.96 to 1.45)
Atropine (two or more tests)
Diseases of genitourinary system (N00-N99) 2 5.83 (0.64 to 25.00)
*P<0.05, **P<0.01.
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of follow-up was over 40 years and should be sufficient
for major long term risks to emerge.
Previous research
Onepossible explanation for the excessmortality is the
chemical exposures received by the veterans or other
aspects of the experience of visiting PortonDown. The
bestpreviousevidence for long termeffectsonhealthof
chemical warfare agents relates to the vesicant sulphur
mustard. Increased mortality from respiratory cancer
was noted inUS casualties from sulphurmustard in the
firstworldwar19 20 and inUKdisabilitypensioners from
the first world war who had been affected by sulphur
mustard.21 UK workers who manufactured sulphur
mustard in the second world war had raised mortality
from malignant and non-malignant respiratory
disease,22 and there were similar findings from
Japan.23 Iranian authors associated sulphur mustard
exposure in the Iran-Iraqwar (1980-8) with respiratory
disorders.24 There was no evidence of these effects in
US navy veterans exposed experimentally to sulphur
mustard.10 In Porton Down veterans with exposure to
sulphur mustard, there was an 8% excess mortality
from respiratory cancers and a 2% excess from non-
malignant respiratory diseases, but these were not
statistically significant and the findings in the “high”
exposure subgroups were inconsistent. The probable
explanation is that, whereas manufacturing workers
accumulated months or years of exposure in repeated
shifts, servicemen spent only days or weeks in these
experimental programmes and the number of
instances of exposure was fewer. Furthermore, in
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many of the tests the veterans wore protective
equipment, which would have reduced their uptake
of sulphur mustard.14
There have been few previous studies on the long
term effects of these chemicals other than sulphur
mustard.6-9 Although nitrogen mustard has been asso-
ciated with leukaemias,25 mortality from lymphatic and
haematopoietic cancers was not increased in this study.
Our findings suggest that Lewisite exposure in Porton
Downveteransmight be associatedwithmortality from
cancers of the trachea, bronchus, and lung.12
Interpretation
The associationswe found between chemical exposure
group and cause specific mortality are difficult to
interpret. While they might represent effects of
exposure at PortonDown, it is also possible that Porton
Down and non-PortonDown veterans differed inways
that relate to mortality, leading to confounding. For
example, the longer total military service of Porton
Down veterans might imply differences in military
factors such as overseas postings. We did not collect
information about lifestyle factors that affect mortality,
of which the most important is smoking. This limits
interpretation, particularly of the excess of deaths
attributed to circulatory causes, which are associated
with smoking.Although the longerdurationofmilitary
service in PortonDown veterans might indicate health
related survival, the all cause mortality rate ratio was
unchanged when we restricted analysis to those with
two or more years of service.
The largenumber of outcomes and exposuresmeans
that some significant associations might have occurred
by chance. On the other hand, we might have missed
somegenuine risks.Another potential limitation of this
study, shared by all analyses of underlying cause of
death, is that it is most informative about diseases with
poor survival.
Summary
This large cohort study with detailed information on
chemical exposure provides insights into the long term
health of PortonDown veterans.Mortality was slightly
higher than in non-Porton Down veterans but with the
lack of information about other important factors, such
as smoking or service overseas, we cannot attribute a
small excess such as this to chemical exposures at
Porton Down.
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